Clynes M - Search Results

1

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.

Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Browne BC, et al. Among authors: clynes m. Ann Oncol. 2011 Jan;22(1):68-73. doi: 10.1093/annonc/mdq349. Epub 2010 Jul 20. Ann Oncol. 2011. PMID: 20647220 Free article.

2

Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.

O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M. O'Connor R, et al. Among authors: clynes m. Anticancer Res. 2004 Mar-Apr;24(2A):457-64. Anticancer Res. 2004. PMID: 15152944 Free article.

3

Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.

Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M. Larkin A, et al. Among authors: clynes m. Int J Cancer. 2004 Nov 1;112(2):286-94. doi: 10.1002/ijc.20369. Int J Cancer. 2004. PMID: 15352042

4

A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.

Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, Clynes M. Glynn SA, et al. Among authors: clynes m. Br J Cancer. 2004 Nov 15;91(10):1800-7. doi: 10.1038/sj.bjc.6602221. Br J Cancer. 2004. PMID: 15505620 Free PMC article.

5

Molecular markers of multiple drug resistance in breast cancer.

O'Driscoll L, Clynes M. O'Driscoll L, et al. Among authors: clynes m. Chemotherapy. 2006;52(3):125-9. doi: 10.1159/000092540. Epub 2006 Apr 4. Chemotherapy. 2006. PMID: 16612055 Review.

6

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. O'Connor R, et al. Among authors: clynes m. Cancer Chemother Pharmacol. 2007 Jan;59(1):79-87. doi: 10.1007/s00280-006-0240-7. Epub 2006 Apr 27. Cancer Chemother Pharmacol. 2007. PMID: 16642371 Clinical Trial.

7

Biomarkers and multiple drug resistance in breast cancer.

O'Driscoll L, Clynes M. O'Driscoll L, et al. Among authors: clynes m. Curr Cancer Drug Targets. 2006 Aug;6(5):365-84. doi: 10.2174/156800906777723958. Curr Cancer Drug Targets. 2006. PMID: 16918307 Review.

8

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.

O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M. O'Driscoll L, et al. Among authors: clynes m. Mol Cancer. 2006 Dec 15;5:74. doi: 10.1186/1476-4598-5-74. Mol Cancer. 2006. PMID: 17173689 Free PMC article.

9

Prevalence and prognostic and predictive relevance of PRAME in breast cancer.

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L. Doolan P, et al. Among authors: clynes m. Breast Cancer Res Treat. 2008 May;109(2):359-65. doi: 10.1007/s10549-007-9643-3. Epub 2007 Jul 12. Breast Cancer Res Treat. 2008. PMID: 17624586

10

MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.

O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. O'Driscoll L, et al. Among authors: clynes m. Anticancer Res. 2007 Jul-Aug;27(4B):2115-20. Anticancer Res. 2007. PMID: 17695494 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

326 results

Search Page

Filters